Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2005

Open Access 01-12-2005 | Primary research

Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression

Authors: Heather Ervin, James L Cox

Published in: Cancer Cell International | Issue 1/2005

Login to get access

Abstract

Background

Tumor metastasis is a frequent cause of treatment failure for cancer patients. A key feature of metastatic cancer cells is their invasive ability. Cysteine proteases contribute to invasive properties of many cancer cell types. To analyze the contribution of cysteine proteases to metastasis we have over-expressed in B16 melanoma cells the natural cysteine protease inhibitor, cystatin C. We measured in vitro invasion of cystatin over-expression clones with Boyden chamber type assays. Tail-vein injections of cells were used to compare lung tumor colonization. Subcutaneous tumor growth and tumor cell metastasis from primary tumors were also analyzed. Apoptosis of tumor cells was measured in lung tissues following melanoma cell injection.

Results

Results show the in vitro invasion of cystatin C over-expressing cells was dramatically inhibited. Lung tumor colonization was also reduced. Increased tumor cell apoptosis was found to be an important factor and may be related to the reduced tumor burden noted in this system of melanoma metastasis.

Conclusion

Cysteine proteases therefore, may be a target for future anti-metastatic therapies.
Appendix
Available only for authorised users
Literature
1.
Engers R, Gabbert HE: Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol. 2000, 126: 682-92. 10.1007/s004320000148.CrossRefPubMed
2.
Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003, 3: 453-8. 10.1038/nrc1098.CrossRefPubMed
3.
Rosen LS: Angiogenesis inhibition in solid tumors. Cancer J. 2001, 7 (Suppl 3): S120-8.PubMed
4.
Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G, Schnorr D, Loening SA: Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer. 1999, 35: 138-44. 10.1016/S0959-8049(98)00273-1.CrossRefPubMed
5.
Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF, Lah TT: Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem. 2003, 384: 447-55. 10.1515/BC.2003.050.CrossRefPubMed
6.
DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE: Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol. 1997, 425: 89-97.CrossRefPubMed
7.
Podgorski I, Sloane BF: Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp. 2003, 263-76.
8.
Hazen LG, Bleeker FE, Lauritzen B, Bahns S, Song J, Jonker A, Van Diel BE, Lyon H, Hansen U, Kohler A, Van Noorden CJ: Comparative localization of cathepsin B protein and activity in colorectal cancer. J Histochem Cytochem. 2000, 48: 1421-30.CrossRefPubMed
9.
Chambers AF, Colella R, Denhardt DT, Wilson SM: Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinog. 1992, 5: 238-45.CrossRefPubMed
10.
Turk B, Turk V, Turk D: Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem. 1997, 378: 141-50.PubMed
11.
Cox JL, Sexton PS, Green TJ, Darmani NA: Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res. 1999, 9: 369-74.CrossRefPubMed
12.
Sexton PS, Cox JL: Inhibition of motility and invasion of B16 melanoma by the overexpression of cystatin C. Melanoma Res. 1997, 7: 97-101.CrossRefPubMed
13.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. 1989, Cold Spring Harbor, NY: Cold Spring Harbor Press
14.
Anastasi A, Brown MA, Kembhavi AA, Nicklin MJ, Sayers CA, Sunter DC, Barrett AJ: Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J. 1983, 211: 129-38.PubMedCentralCrossRefPubMed
15.
Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 1994, 54: 5467-73.PubMed
16.
Paraoan L, Ratnayaka A, Spiller DG, Hiscott P, White MR, Grierson I: Unexpected intracellular localization of the AMD-associated cystatin C variant. Traffic. 2004, 5: 884-95. 10.1111/j.1600-0854.2004.00230.x.CrossRefPubMed
17.
Albini A: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer research. 1987, 47: 3239-3245.PubMed
18.
Chambers AF, Schmidt EE, MacDonald IC, Morris VL, Groom AC: Early steps in hematogenous metastasis of B16F1 melanoma cells in chick embryos studied by high-resolution intravital videomicroscopy. J Natl Cancer Inst. 1992, 84: 797-803.CrossRefPubMed
19.
Morris VL, Tuck AB, Wilson SM, Percy D, Chambers AF: Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin Exp Metastasis. 1993, 11: 103-12. 10.1007/BF00880071.CrossRefPubMed
20.
Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris UL, Chambers AF, Groom AC: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 1994, 54: 4791-7.PubMed
21.
Van Noorden CJ, Jonges TG, Meade-Tollin LC, Smith RE, Koehler A: In vivo inhibition of cysteine proteinases delays the onset of growth of human pancreatic cancer explants. Br J Cancer. 2000, 82: 931-6. 10.1054/bjoc.1999.1021.PubMedCentralCrossRefPubMed
22.
Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002, 29: 15-8. 10.1053/sonc.2002.37263.CrossRefPubMed
23.
Erdel M, Trefz G, Spiess E, Habermaas S, Spring H, Lah T, Ebert W: Localization of cathepsin B in two human lung cancer cell lines. J Histochem Cytochem. 1990, 38: 1313-21.CrossRefPubMed
24.
Van Noorden CJ, Jonges TG, Van Marle J, Bissell ER, Griffini P, Jans M, Snel J, Smith RE: Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin Exp Metastasis. 1998, 16: 159-67. 10.1023/A:1006524321335.CrossRefPubMed
25.
Konduri SD, Yanamandra N, Siddique K, Joseph A, Dinh DH, Olivero WC, Gujrate M, Kouraklis G, Swaroop A, Kyritsis AP, Rao JS: Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene. 2002, 21: 8705-12. 10.1038/sj.onc.1205949.CrossRefPubMed
Metadata
Title
Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression
Authors
Heather Ervin
James L Cox
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2005
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-5-14

Other articles of this Issue 1/2005

Cancer Cell International 1/2005 Go to the issue

Primary research

Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity

Primary research

U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3

Hypothesis

On evolutionary origin of cancer

Primary research

Proton-Induced X-ray Emission (PIXE) Analysis and DNA-chain Break study in rat hepatocarcinogenesis: A possible chemopreventive role by combined supplementation of vanadium and beta-carotene

Primary research

Functional and structural characteristics of anticancer peptide Pep27 analogues

Primary research

Responses of genes involved in cell cycle control to diverse DNA damaging chemicals in human lung adenocarcinoma A549 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits